Bringing Next Gen EP Device to Market
BioSig Technologies (OTCQB:BSGM) is a medical device company that has developed a proprietary technology platform targeting the rapidly growing electrophysiology (EP) device market. EP devices are used in the treatment of cardiac arrhythmias, which can lead to stroke or even death. The current standard of care is cardiac catheter ablation which has a low efficacy rate.
BioSig Technologies’ goal is to bring to market an advanced biomedical signal processing technology that can address unmet needs for the treatments of challenging and chronic diseases such as arrhythmias. The company is advancing towards commercialization of its PURE EPTM System which is designed to improve the clarity of clinical signals available for EP studies and ablation procedures.